Allen Ho is a Dermatology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
221 Longwood Ave
Boston, MA 021155804
Telephone
617-732-5500Registry record last updated 21 Jul 2022.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Stryker CorporationProgram year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
46.4%Azole Antifungal21.8%Ketoconazole100%Part D≥15 patientsNitroimidazole Antimicrobial10.1%Metronidazole100%Part D<11 patients+ 2 more classes in this area
Dermatology
31.8%Corticosteroid22.9%Triamcinolone Acetonide100%Part D≥22 patientsInterleukin-4 Receptor alpha Antagonist8.9%Dupixent Pen100%Part D<11 patientsSensory organs
11.7%Corticosteroid11.7%Clobetasol Propionate100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Mechanisms of IL-23 receptor-mediated pathogenicity in CD4+ T cells
Brigham and Women'S Hospital
FY2025$168,848K08AR079007 - Mechanisms of IL-23 receptor-mediated pathogenicity in CD4+ T cells
Brigham and Women'S Hospital
FY2024$168,848K08AR079007 - Mechanisms of IL-23 receptor-mediated pathogenicity in CD4+ T cells
Brigham and Women'S Hospital
FY2023$168,848K08AR079007
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”